Format

Send to

Choose Destination
Semin Cutan Med Surg. 2017 Sep;36(3):124-130. doi: 10.12788/j.sder.2017.0137.

Atopic dermatitis: emerging therapies.

Author information

1
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA. simpsone@ohsu.edu.
2
Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA.
3
Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA.
4
Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center, Rochester, New York, USA.

Abstract

Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

KEYWORDS:

PMID:
28895959
DOI:
10.12788/j.sder.2017.0137

Supplemental Content

Loading ...
Support Center